



The National Centre
for Research and Development

REQUEST FOR QUOTATION dated on **02 03 2018 G**

I. ORDERING PARTY:

Selvita S.A.
Ul. Bobrzyńskiego 14
30-348 Kraków
VAT EU: 679 29 42 955

DELIVERY ADDRESS:

Selvita S.A.
Ul. Bobrzyńskiego 14
30-348 Kraków
Poland

II. DESCRIPTION OF THE ORDER:

Vendor should make an offer for objects (or part of objects) presented below:

No	Name	CPV CODE	Amount	Price w/o VAT
----	------	-------------	--------	---------------------

1.	<p>Set of 2 clones:</p> <p>1. MLLT1 human tagged ORF clone; 10 ug</p> <ul style="list-style-type: none"> purified plasmid DNA of human MLLT1 ORF in lentiviral backbone the insert is sequenced before inserting into the final vector and end-sequenced to assure correct insertion in the vector ORF size: 1677 bp MLLT1 tagged at C' terminus with Myc-DDK ORF and P2A-Puromycin resistant gene under one CMV promoter based on lentiviral packaging system KOZAK sequence and WPRE included in the construct ion-exchange column purified, transfection-ready dried plasmid DNA KOZAK sequence and WPRE chloramphenicol selection for bacterial cells ORF sequence: "ATGGACAATCAGTGCACCGTCCAGGTGAGGTTAGAGCTGGG GCATCGCGCCCAACTGCGCAAGAAGCCCACCACGGAGGGGT TCACTCACGACTGGATGGTGTGGTCCGCGGCCCGGAGCAAT GTGACATCCAGCACTTCGTGGAGAAGGTGGTCTTCTGGCTGC ACGACAGCTTCCCAAGCCAGACGCGTGTGCAAGGAGCCC CCCTACAAAGTAGAGGAGTCGGGGTACGCTGGCTTCATCATG CCCATCGAGGTGCACTTCAAAAACAAGGAGGAGCCGAGGAA GGTCTGCTTACCTACGACCTGTTCTGAACCTGGAAGGCAA CCCGCCCGTGAACCACCTGCGCTGCGAGAAGCTCACCTTCAA CAACCCACCACGGAGTTCCGGTACAAGCTCCTGCGGGCCG GCGGGGTGATGGTAATGCCCGAAGGAGCAGACACGGTGTCC AGGCCAGTCCCGACTACCCATGTTACCCACAATTCCACTCT CTGCCTTCTGACCCCAAGAAGACCAACCATCCACGGCT CCAAGGACGCCAACAAGGAGAGCAGCAAGACCTCCAAGCCA CACAAGGTGACCAAGGAGCACCGGGAGCGGCCCGCAAAG ACTCCGAGAGCAAGAGCTCCTCAAGGAGCTGGAGCGTGAG CAGGCCAAAAGCTCAAGGACACCTCGCGGAAGCTGGGCGA GGGCCGGCTGCCAAGGAGGAGAAGGCGCCACCGCCCAAG GCTGCCTTCAAGGAACCCAAGATGGCCCTGAAAGAGACCAA GCTGAAAAGCACGTCCCCAAGGGTGGGCCCCACCCCCAC CCCCACCCACCCCGGGCTTCCAGCAAGCGGCCGGCCACC GCCGACTCGCAAAGCCAGCGCCAAGAAGCAGAAGAAGA GCAGCTCGAAGGGTCCCGGAGTGCTCCAGGCACCTCGCCC CGCACCTCCTCCTCCTCCTTCTCGGACAAGAAGCCGGCCA AGGACAAGAGCAGCACCAGAGGGGAGAAGGTGAAGGCCG AGAGTGAGCCCCGGGAGGCCAAAAGGCCCTGGAGGTGGA GGAGTCCAACCTCAGAGGACGAGGCCTCCTCAAGTCCGAGT CTGCCAGTCAAGCCCGTCCAACCTCCAGCTCCAGCTCAGACT CCAGCTCAGACTCAGACTTCGAGCCATCCAGAACCACAGCC AAGGACCCCTGCGCTCCATGGTGGAGGACCTGCAGTCCGAG GAGTCCGACGAGGACGACTCTTCGTCAGGCGAGGAGGCTGC 	336965 00-0	1	
----	---	----------------	---	--

CGGCAAGACCAACCCGGGGAGGGACTCCAGGTTGAGCTTCA
 GCGACAGCGAGAGTGACAACAGCGCCGACTCCTCCCTGCC
 AGCCGTGAGCCCCACCCCCCAGAAGCCACCCCGCCCAAC
 AGCAAGGTGTCAGGCCGGAGGAGCCCCGAGTCTGCAGCAA
 GCCTGAGAAGATCCTCAAGAAGGGCACCTACGACAAGGCCT
 ACACGGATGAGCTGGTGGAGCTACACCGGAGGCTGATGGCG
 CTGCGGGAGCGCAACGTGCTGCAGCAGATTGTGAATCTGATC
 GAGGAGACTGGCCACTTCAATGTCACCAACACCACCTTCGAC
 TTCGACCTCTTCTCCCTGGACGAGACCACCGTGCGCAAACCTG
 CAGAGCTGCCTGGAGGCCGTGGCCACA"

2. Clone of mutated ORF of the clone above at NT 232 and 233 from TA to GC; 10 ug

- purified plasmid DNA of mutated human MLLT1 Y78A ORF in lentiviral backbone
- the insert is sequenced before inserting into the final vector and end-sequenced to assure correct insertion in the vector
- MLLT1 Y78A tagged at C' terminus with Myc-DDK
- ORF and P2A-Puromycin resistant gene under one CMV promoter
- based lentiviral packaging system
- KOZAK sequence and WPRE included in the construct
- chloramphenicol selection for bacterial cells
- ORF sequence:

"ATGGACAATCAGTGCACCGTCCAGGTGAGGTTAGAGCTGGG
 GCATCGCGCCCAACTGCGCAAGAAGCCACCACGGAGGGGT
 TCACTCAGCACTGGATGGTGTGTTGTCGCGGCCCGAGCAAT
 GTGACATCCAGCACTTCGTGGAGAAGGTGGTCTTCTGGCTGC
 ACGACAGCTTCCCAAGCCAGACGCGTGTGCAAGGAGCCC
 CCTACAAAGTAGAGGAGTCGGGGGCCGCTGGCTTCATCATG
 CCCATCGAGGTGCACTTCAAAAACAAGGAGGAGCCGAGGAA
 GGTCTGCTTACCTACGACCTGTTCTGAACCTGGAAGGCAA
 CCCGCCGTGAACCACCTGCGCTGCGAGAAGCTCACCTTCAA
 CAACCCACCACGGAGTTCCGGTACAAGCTCCTGCGGGCCG
 GCGGGGTGATGGTAATGCCCGAAGGAGCAGACACGGTGTCC
 AGGCCAGTCCCGACTACCCCATGTTACCCACAATTCCACTCT
 CTGCCTTCTGACCCCAAGAAGACCAACCATCCCACGGCT
 CCAAGGACGCCAACAAGGAGAGCAGCAAGACCTCCAAGCCA
 CACAAGGTGACCAAGGAGCACCGGGAGCGCCCCGCAAAG
 ACTCCGAGAGCAAGAGCTCCTCCAAGGAGCTGGAGCGTGAG
 CAGGCCAAAAGCTCCAAGGACACCTCGCGGAAGCTGGGCGA
 GGGCCGGCTGCCCAAGGAGGAGAAGGCGCCACCGCCCAAG
 GCTGCCTTCAAGGAACCCAAGATGGCCCTGAAAGAGACCAA
 GCTGGAAGACAGTCCCCAAGGGTGGGCCCCACCCCCAC
 CCCCACCCACCCCGGGCTTCCAGCAAGCGGCCGGCCACC
 GCCGACTCGCAAAGCCAGCGCCAAGAAGCAGAAGAAGA
 GCAGCTCGAAGGGTCCCGGAGTGCTCCAGGCACCTCGCCC
 CGCACCTCCTCCTCCTCCTTCTCGGACAAGAAGCCGGCCA

	<p>AGGACAAGAGCAGCACCAGAGGGGAGAAGGTGAAGGCCG AGAGTGAGCCCCGGGAGGCCAAAAAGCCCTGGAGGTGGA GGAGTCCAACTCAGAGGACGAGGCCTCCTCAAGTCCGAGT CTGCCAGTCAAGCCCGTCCAACCTCCAGCTCCAGCTCAGACT CCAGCTCAGACTCAGACTTCGAGCCATCCCAGAACCACAGCC AAGGACCCCTGCGCTCCATGGTGGAGGACCTGCAGTCCGAG GAGTCCGACGAGGACGACTCTTCGTCAGGCGAGGAGGCTGC CGGCAAGACCAACCCGGGGAGGGACTCCAGGTTGAGCTTCA GCGACAGCGAGAGTGACAACAGCGCCGACTCCTCCCTGCC AGCCGTGAGCCCCACCCCCCAGAAGCCACCCCGCCCAAC AGCAAGGTGTCAGGCCGGAGGAGCCCCGAGTCCTGCAGCAA GCCTGAGAAGATCCTCAAGAAGGGCACCTACGACAAGGCCT ACACGGATGAGCTGGTGGAGTACACCGGAGGCTGATGGCG CTGCGGGAGCGCAACGTGCTGCAGCAGATTGTGAATCTGATC GAGGAGACTGGCCACTTCAATGTCACCAACACCACCTTCGAC TTCGACCTCTTCTCCCTGGACGAGACCACCGTGCGCAAACCTG CAGAGCTGCCTGGAGGCCGTGGCCACA"</p>			
--	--	--	--	--

2.	<p>Anti-HA tag antibody, 100 ug</p> <ul style="list-style-type: none"> • from influenza hemagglutinin epitope: YPYDVPDYA • mouse monoclonal to HA tag • isotype: IgG3 • conjugated to KLH • concentration: 100 µg at 1 mg/ml • formulation: 0.05% Sodium Azide and PBS • purified from TCS • application: ChIP/Chip, WB, ICC, IP, ICC/IF 	249560 00-0	1	
----	---	----------------	---	--

Buyer reserves the right to purchase different quantity of the product than stated in the query.

III. DEADLINE OF THE DELIVERY

Delivery of an order should be no later than **56 calendar days**.

IV. DESCRIPTION FOR PREPARING OFFERS

The Vendor should make the offer in Polish or English.

The offer should include:

1. The full name of a Vendor.
2. Address and phone number of the Vendor and contact person.
3. Price for order.
4. **Offer validity period**- at least **30 calendar days**.
5. Delivery time (in days). **If range of time given, the upper value will be considered.**
6. It is possible to make an offer for a part of an order.

In the absence of information about delivery time and offer validity period, Ordering Party assumes that they comply with the requirements indicated in RFQ.

V. EVALUATION CRITERIA:

1. Price: 100%.

VI. PLACE AND THE DEADLINE FOR SUBMISSION OF OFFERS

1. The offer must be submitted by **09th March 2018 by the end of the day**.
2. Offer must be sent to the e-mail address: tenders@selvita.com, by fax to: +48 12 297 47 01, courier or delivered personally:
Selvita S.A.
ul. Bobrzyńskiego 14
30-348 Kraków



The National Centre
for Research and Development

3. Offers received after the deadline will not be taken into consideration.